Furthermore, research in other hematological malignancies, such as Hodgkin lymphoma, has demonstrated the expression of ADAM10 and the potential for its inhibition to exert anti-tumor effects and enhance the activity of other therapeutic agents (22, 23).A deeper understanding of these processes may pave the way for the development of targeted therapeutic strategies aimed at modulating ADAM10 activity in these hematological malignancies. Here, ADAM10 is linked to neoplasm.